ACA
BCLI

Aptus Capital Advisors’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Aptus Capital Advisors’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-691
Closed -$46K – 802
2022
Q3 		$46K Buy
691
+10
+1% +$502 ﹤0.01% 559
2022
Q2 		$28K Sell
681
-152
-18% -$6.84K ﹤0.01% 515
2022
Q1 		$42K Hold
833
– – ﹤0.01% 521
2021
Q4 		$50K Sell
833
-234
-22% -$11.5K ﹤0.01% 427
2021
Q3 		$53K Sell
1,067
-156
-13% -$8.21K ﹤0.01% 408
2021
Q2 		$70K Buy
1,223
+153
+14% +$8.18K ﹤0.01% 412
2021
Q1 		$61K Sell
1,070
-1,207
-53% -$91.2K ﹤0.01% 391
2020
Q4 		$154K Buy
+2,277
New +$310K 0.01% 316

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Aptus Capital Advisors's BCLI Position: Q4 2022 in Review

Aptus Capital Advisors sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2022, closing a stake of 691 shares — an estimated $46K sold.

Aptus Capital Advisors first reported a position in BCLI in Q4 2020 and held it in 8 quarters. The position peaked at $154K in Q4 2020. 43 funds tracked by Wall St. Rank hold BCLI as of Q4 2022.

  • Aptus Capital Advisors reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2022 after selling out during the quarter.
  • Aptus Capital Advisors sold 691 BRAINSTORM CELL THERAPUTC shares in Q4 2022, an estimated $46K.
  • Aptus Capital Advisors first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2020 and held it in 8 quarters.
  • Aptus Capital Advisors's BRAINSTORM CELL THERAPUTC position peaked at $154K in Q4 2020.
  • 43 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2022.

Based on Aptus Capital Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.